Scopus Press Releases: - Major Corporations Choose Scopus to Drive R&D Business

Major Corporations Choose Scopus to Drive R&D Business

Amsterdam, January 13, 2005

Henkel and Boehringer Ingelheim, two of the world's leading companies are among the first corporations to invest in Scopus, the world's largest Abstract and Indexing (A&I) database from Elsevier. Both companies are recognised internationally for their strengths in research and development (R&D), which is a key part of their business model. Their decision to choose Scopus as a multi-disciplinary tool that delivers their scientists better search results is a strong endorsement for Scopus' time-saving efficiency. Easier, faster searching with better results helps streamline the research process and ultimately impacts on the bottom line.

Boehringer Ingelheim spends more than one fifth of net sales in its largest business segment, Prescription Medicines, on research and development.1 Dr. Oliver Renn, Head of the Scientific Library, Department of Quality & Records Management said that "the commercial sector is highly competitive and it is important for us to have the best when it comes to research resources. We believe that access to Scopus will increase the quality and productivity of our R&D output, so that our customers get the best possible products from our company."

Jaco Zijlstra, Director of Scopus, said "In the commercial environment, the timing of scientific breakthroughs impacts on the value of the business. Our corporate clients recognise that Scopus potentially speeds up part of the research process by delivering quality results in less time."

Dr. Christoph Haxel, Director of Henkel Corporate Scientific Services, said "Scopus gives our scientists access to the right information in a timely fashion and frees them up so that they can concentrate on their research. Scopus offers our global research and development teams the first search tool that combines searches of subscription based literature and information on the Internet in an efficient and economical way. We believe Scopus will make a positive contribution to the development of Henkel's innovative brands and technologies."

Scopus has won high-profile customers in the corporate and academic sector since its launch eight weeks ago and is being adopted at a very high pace. Leading corporate and academic institutions in North America, Latin America, Asia, Australia, Europe and the Middle East have signed deals. Henkel and Boehringer Ingelheim have joined the growing list of quality-driven organisations who believe Scopus will positively impact on their research.

Scopus was created with the end-user in mind. It is the result of over two years of collaboration with librarians and researchers across the globe. They had a clear vision of what Scopus should be and what it had to deliver to the scientific community in terms of quality, depth and scope of information. To date over 50 organisations and institutions have subscribed to Scopus and the user community exceeds 600,000. Corporate and academic scientific researchers will reap the benefits of the time they can now save in the research process with Scopus.

"We believe that Scopus is an invaluable investment for our company," added Christoph Haxel, "when you analyse the cost versus the man-hours saved by removing irrelevant information and dead internet links, Scopus is right on target. It gets our scientists where they need to go and quality is guaranteed."

For more information on Scopus please visit www.info.scopus.com.

Notes to Editors

For more information, or to speak with the Scopus development team, please contact the Scopus Press Office on +1 703 255 0277 or email news@scopus.com

Scopus Background

Scopus is Elsevier's highly anticipated, full text-linking abstract and indexing (A&I) database
The first fully functioning version of Scopus was released to select libraries for final testing and user trials on 15th March 2004. Full commercial release of Scopus is 3rd November 2004
Scopus was conceived solely in response to librarian and user requirements, and is the result of a two year collaboration with librarians and researchers at over 20 of the world's foremost institutions
At the heart of Scopus is the biggest A&I database of scientific literature ever assembled, covering titles from over 4000 STM publishers. Scopus also simultaneously searches the scientific Web using the science-only Internet search engine, Scirus
The Scopus user interface offers easy-to-use searching straight from the home page and intuitive browsing tools
Users can link to their entitled full-text articles in one click, making ‘dead-links' a frustration of the past
Industry-leading levels of reliability and powerful delivery are coupled with local customer support, customer-specific usage reports which have just been awarded COUNTER-compliant status, as well as on- and off-site training, to make Scopus a complete package for librarians and end-users

About Elsevier
Elsevier (www.elsevier.com) is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 6,800 employees in 86 offices worldwide publish more than 1,800 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.news.scopus.com/), bibliographic databases, and online reference works.

Elsevieris a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About Boehringer Ingelheim (Germany)
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 152 affiliates in 45 countries and more than 34,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2003, Boehringer Ingelheim posted net sales of 7.4 billion euro while spending more than one fifth of net sales in its largest business segment, Prescription Medicines, on research and development. (Source: Boehringer Ingelheim website)

About Henkel
“Henkel - A Brand like a Friend”. Henkel is a leader with brands and technologies that make people's lives easier, better and more beautiful. The Henkel Group operates in three strategic business areas – Home Care, Personal Care, and Adhesives, Sealants and Surface Treatment. In fiscal 2003 the Henkel Group generated sales of 9.436 billion euros and an operating profit (EBIT) of 706 million euros. More than 50,000 employees work for the Henkel Group worldwide. People in 125 countries around the world trust in brands and technologies from Henkel. (Source: Henkel website)